-
EQRx's Lung Cancer Candidate Shows Improved Progression-Free Survival Versus Placebo
Monday, August 8, 2022 - 7:04am | 309EQRx Inc (NASDAQ: EQRX) announced the presentation of updated data from the Phase 3 GEMSTONE-301 trial of sugemalimab in non-small cell lung cancer (NSCLC). As of the March data cutoff, the final progression-free survival (PFS) analysis showed that sugemalimab continued to...
-
Merck, Athenex Join Forces To Evaluate Oraxol/Keytruda Combo In Lung Cancer
Monday, May 16, 2022 - 12:24pm | 212Athenex Inc (NASDAQ: ATNX) announced a clinical trial collaboration and supply agreement with Merck Co & Inc (NYSE: MRK). The agreement applies to the expansion phase of the Phase 1 clinical trial evaluating Athenex's oral paclitaxel combined with Merck's...
-
Bristol Myers' Neoadjuvant Opdivo/Chemo Therapy Yet To Reach Overall Survival Endpoint In Early-Stage Lung Cancer
Monday, April 11, 2022 - 3:07pm | 318Bristol Myers Squibb Co (NYSE: BMY) announced results from the Phase 3 CheckMate -816 trial in resectable non-small cell lung cancer (NSCLC). The data showed that neoadjuvant treatment with three Opdivo (nivolumab) cycles combined with chemotherapy significantly improved event-free...
-
Lilly Presents Updated Data On Retevmo In Advanced RET Fusion-Positive Lung Cancer
Friday, April 1, 2022 - 11:07am | 257Eli Lilly And Co (NYSE: LLY) announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo (selpercatinib) in patients with RET fusion-positive non-small cell lung cancer (NSCLC). The updated analysis utilized a June 15, 2021, data cut-off. Among 247...
-
Why Are Immutep Shares Trading Higher?
Wednesday, March 30, 2022 - 7:52am | 332Immutep Limited (NASDAQ: IMMP) has announced new interim data from the Phase 2 TACTI002 trial of eftilagimod alpha (efti or IMP321), combined with Merck & Co Inc's Keytruda (pembrolizumab). The trial included 36 patients with PD-L1 unselected 2nd line PD-X...
-
Cullinan Oncology Lead Cancer Program Shows Confirmed ORR Of 41% In Lung Cancer Setting
Tuesday, March 29, 2022 - 7:54am | 329Cullinan Oncology Inc (NASDAQ: CGEM) announced clinical and regulatory updates from Phase 1/2a trial of CLN-081 in a non-small cell lung cancer (NSCLC) setting. The trial includes NSCLC patients harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations progressed...
-
Merck Lays Out Keytruda Data In Post Surgery Early-Stage Lung Cancer Setting
Friday, March 18, 2022 - 8:18am | 251Merck & Co Inc (NYSE: MRK) announced results from the Phase 3 KEYNOTE-091 trial evaluating Keytruda compared to placebo for adjuvant treatment of non-small cell lung cancer (NSCLC). The trial included patients with stage IB (≥4 centimeters) to IIIA NSCLC following surgical resection (...
-
Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers
Wednesday, March 16, 2022 - 9:21am | 286The FDA has signed off Iovance Biotherapeutics Inc's (NASDAQ: IOVA) Investigational New Drug Application (IND) first genetically modified TIL therapy, IOV-4001, for unresectable or metastatic melanoma and stage III or IV non-small-cell lung cancer (NSCLC). IOV-4001 leverages the...
-
Junshi Biosciences - Coherus Toripalimab Chemo Combo Met Survival Endpoints In Lung Cancer Setting
Tuesday, March 15, 2022 - 12:06pm | 260Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS) have shared biomarker analyses from the CHOICE-01 Phase 3 trial of toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC)....
-
BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC
Tuesday, March 8, 2022 - 12:43pm | 313BioNTech SE (NASDAQ: BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to its FixVac candidate BNT116 combined with Libtayo (cemiplimab) in advanced non-small-cell lung cancer (NSCLC). Under the terms of the agreement,...
-
Spectrum Pharma Highlights Poziotinib Data In Treatment-Naïve Lung Cancer Setting
Monday, March 7, 2022 - 8:54am | 276Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) announced the presentation of safety and efficacy results from Cohort 4 of the ZENITH20 trial evaluating poziotinib in various non-small cell lung cancer settings. The data comes from 70 first-line patients with non-small lung cancer (...
-
FDA Approves Bristol Myers' Opdivo Plus Chemo In Neoadjuvant Lung Cancer Setting
Monday, March 7, 2022 - 8:50am | 277The FDA has approved Bristol Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) in combination with platinum-doublet chemotherapy for resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting. The agency approved the Opdivo combo just five days after accepting...
-
Mirati Therapeutics' Adagrasib Application Under FDA Review For Lung Cancer Setting
Wednesday, February 16, 2022 - 9:21am | 278The FDA has accepted for review Mirati Therapeutics Inc's (NASDAQ: MRTX) marketing application seeking approval for adagrasib for non-small cell lung cancer (NSCLC). The application covers NSCLC patients harboring the KRASG12C mutation who have received at least one prior...
-
Pfizer's Lorlatinib Scores European Approval In ALK-Positive Lung Cancer
Friday, January 28, 2022 - 1:28pm | 256The European Commission has approved Pfizer Inc's (NYSE: PFE) Lorviqua (lorlatinib) for a form of advanced non-small-cell lung cancer (NSCLC). Lorlatinib is available in the U.S. under the brand name Lorbrena. The approval covers lorlatinib as monotherapy for anaplastic lymphoma...
-
Amgen's Lumakras Approved In Japan For Pretreated Lung Cancer Patients
Thursday, January 20, 2022 - 9:52am | 304Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) has been approved in Japan for KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer (NSCLC) progressed after systemic anticancer therapy. Lumakras is now approved in nearly 40 countries....